2020
Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report
Zisook S, Johnson G, Hicks P, Chen P, Beresford T, Michalets J, Rao S, Thase M, Wilcox J, Sevilimedu V, Mohamed S. Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report. Depression And Anxiety 2020, 38: 185-195. PMID: 33225492, DOI: 10.1002/da.23114.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantHumansQuality of LifeTreatment OutcomeConceptsDepressive symptom severityContinuation treatmentBupropion SRTreatment outcomesTreatment-resistant major depressive disorderSymptom severitySignificant differential treatment effectsContinuation treatment phaseAcute-phase treatmentAbnormal laboratory valuesLower relapse rateMajor depressive disorderQuality of lifeLess anxietyDifferential treatment effectsMore somnolenceDry mouthRelapse rateExtrapyramidal effectsFull remissionWeek 12Continuation phaseTreatment attemptsDepressive disorderLaboratory valuesImpact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S, Johnson GR, Sevilimedu V, Rao SD, Hicks PB, Chen P, Lauro K, Jurjus G, Pilkinton P, Davis L, Wilcox JA, Iranmanesh A, Sapra M, Aslam M, Michalets J, Thase M, Zisook S. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32603560, DOI: 10.4088/jcp.19m13038.Peer-Reviewed Original ResearchConceptsConcurrent posttraumatic stress disorderMajor depressive disorderPosttraumatic stress disorderDepressive disorderVeterans Health Administration medical centersNonpsychotic major depressive disorderStress disorderMini International Neuropsychiatric InterviewAdequate antidepressant treatmentPoor overall outcomeDepressive Symptomatology-Clinician RatedSevere depressive symptomsAntipsychotic augmentationInitial remissionAntidepressant treatmentSuboptimal responseAntipsychotic aripiprazoleCurrent antidepressantsAntidepressant trialsQuick InventoryNeuropsychiatric InterviewClinical trialsMedical CenterRemissionDepressive symptoms
2019
General Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2017
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao S, Pilkinton P, Wilcox J, Iranmanesh A, Sapra M, Jurjus G, Michalets J, Aslam M, Beresford T, Anderson K, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D’Souza D, Larson G, Anderson W, Klatt M, Fareed A, Thompson S, Carrera C, Williams S, Juergens T, Albers L, Nasdahl C, Villarreal G, Winston J, Nogues C, Connolly K, Tapp A, Jones K, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda A, Niculescu A, Fischer B, Loreck D, Rosenlicht N, Lieske S, Finkel M, Little J. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318: 132-145. PMID: 28697253, PMCID: PMC5817471, DOI: 10.1001/jama.2017.8036.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAcute treatment phaseDepressive disorderSwitch groupAdverse effectsTreatment phaseUS Veterans Health Administration medical centersVeterans Health Administration medical centersNonpsychotic major depressive disorderWeeks of treatmentEffects of antidepressantsLikelihood of remissionSignificant treatment differencesBupropion monotherapyRandomized patientsRemission rateBupropion groupSecondary outcomesPrimary outcomeAtypical antipsychoticsDifferent antidepressantsFirst antidepressantClinical trialsCurrent treatmentMedical Center
2016
Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report
Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report. Journal Of Affective Disorders 2016, 206: 232-240. PMID: 27479536, DOI: 10.1016/j.jad.2016.07.023.Peer-Reviewed Original ResearchConceptsMajor depressive disorderClinical featuresDepressive disorderNonpsychotic major depressive disorderInitial standard treatmentNon-veteran samplesU.S. veteran patientsCharacteristics of patientsSample of veteransRecent suicidal ideationPublic health imperativeLasting treatmentMDD treatmentVeteran patientsClinical onsetPsychiatric comorbidityAntidepressant trialsStandard treatmentClinical trialsDepression subtypesRecurrent depressionIndividual patientsSpecific treatmentPatientsSuicidal ideation
2015
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations
Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research 2015, 229: 760-770. PMID: 26279130, DOI: 10.1016/j.psychres.2015.08.005.Peer-Reviewed Original Research
2012
Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression?
Dawes SE, Palmer BW, Meeks T, Golshan S, Kasckow J, Mohamed S, Zisook S. Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression? Neuropsychobiology 2012, 65: 168-172. PMID: 22456094, PMCID: PMC3701889, DOI: 10.1159/000331141.Peer-Reviewed Original ResearchConceptsSchizoaffective disorderCognitive deficitsDepression Rating Scale scoresHamilton Depression Rating ScaleFlexible-dose treatmentAntidepressant treatment responseDepression Rating ScaleTreatment of depressionMajor depressive disorderRating Scale scoresBaseline cognitive statusPlacebo groupAntidepressant medicationCurrent medicationsPlacebo augmentationFunctional disabilityCognitive composite scoreSubsyndromal depressionDepressive disorderSubsyndromal symptomsTreatment responseTreatment groupsDose treatmentScale scoreCognitive status
2009
Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.
Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. The Journal Of Clinical Psychiatry 2009, 70: 906-12. PMID: 19422760, DOI: 10.4088/jcp.08m04450.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntidepressive AgentsAntipsychotic AgentsComorbidityDepressive Disorder, MajorDose-Response Relationship, DrugDrug Therapy, CombinationDrug UtilizationFemaleHospitals, VeteransHumansMaleMiddle AgedUnited StatesUnited States Food and Drug AdministrationVeteransConceptsMajor depressive disorderTreatment of MDDAntipsychotic medicationDepressive disorderService useMental health service useVeterans Affairs patientsUse of antipsychoticsHealth service useComorbid mental illnessDrug Administration approvalLong-term safetyRecent U.S. FoodFirst antipsychoticAntipsychotic dosesAntipsychotic prescriptionsPsychiatric comorbidityComorbid schizophreniaMale genderAdministration approvalVeteran characteristicsMedicationsSchizoaffective disorderAntipsychoticsBipolar disorder
2008
Pharmacotherapy for Older Veterans Diagnosed With Posttraumatic Stress Disorder in Veterans Administration
Mohamed S, Rosenheck R. Pharmacotherapy for Older Veterans Diagnosed With Posttraumatic Stress Disorder in Veterans Administration. American Journal Of Geriatric Psychiatry 2008, 16: 804-812. PMID: 18827226, DOI: 10.1097/jgp.0b013e318173f617.Peer-Reviewed Original ResearchConceptsMental health clinicsSpecialty mental health clinicsPosttraumatic stress disorderOlder veteransHealth clinicsVeterans AdministrationPsychotropic medicationsPharmacotherapy of PTSDStress disorderDegree of undertreatmentPsychotropic medication classesMultivariable logistic regressionUse of medicationsYears of ageRelationship of ageMedication classesMedication utilizationPatients 45Medication usePsychotropic prescriptionsClinic typePrimary careElderly veteransSedative hypnoticsVA services